A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 866 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response... February 16, 2023 FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... August 8, 2025 Why haven’t we cured cancer? – That Cancer Conversation June 14, 2022 Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... February 10, 2025 Load more HOT NEWS EMA Recommends Extension of Indications for Nivolumab and Ipilimumab Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster... Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With...
